ATE229945T1 - Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole - Google Patents

Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole

Info

Publication number
ATE229945T1
ATE229945T1 AT99912221T AT99912221T ATE229945T1 AT E229945 T1 ATE229945 T1 AT E229945T1 AT 99912221 T AT99912221 T AT 99912221T AT 99912221 T AT99912221 T AT 99912221T AT E229945 T1 ATE229945 T1 AT E229945T1
Authority
AT
Austria
Prior art keywords
treatment
cmv infections
thiadiazoles
cmv
thiadiazoles suitable
Prior art date
Application number
AT99912221T
Other languages
English (en)
Inventor
Steven R Turner
Suvit Thaisrivongs
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE229945T1 publication Critical patent/ATE229945T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AT99912221T 1998-03-19 1999-03-16 Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole ATE229945T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7852898P 1998-03-19 1998-03-19
PCT/US1999/003744 WO1999047507A2 (en) 1998-03-19 1999-03-16 1,3,4-thiadiazoles useful for the treatment of cmv infections

Publications (1)

Publication Number Publication Date
ATE229945T1 true ATE229945T1 (de) 2003-01-15

Family

ID=22144610

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912221T ATE229945T1 (de) 1998-03-19 1999-03-16 Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole

Country Status (11)

Country Link
US (1) US6150385A (de)
EP (1) EP1064273B1 (de)
JP (1) JP2002506858A (de)
AT (1) ATE229945T1 (de)
AU (1) AU743489B2 (de)
CA (1) CA2320167A1 (de)
DE (1) DE69904576T2 (de)
DK (1) DK1064273T3 (de)
ES (1) ES2189404T3 (de)
NZ (1) NZ507032A (de)
WO (1) WO1999047507A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500817B1 (en) 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
EP2316827B1 (de) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazin derivate und deren anwendung als therapeutische wirkstoffe
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799667B1 (de) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterozyklische derivate und ihre verwendung als therapeutische wirkstoffe
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2289510A1 (de) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterozyklische Derivate zur Behandlung von durch Stearoyl-Coa-Desaturase-Enzyme verursachten Krankheiten
EP2316458A1 (de) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazin-Derivate zur Verhinderung menschlicher Stearoyl-coa-desaturas
EP1804799B1 (de) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
DE102005014248A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
US8101618B2 (en) * 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
EP2029138A1 (de) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazolderivate als humane stearoyl-coa desaturasehemmer
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
CA2711678A1 (en) * 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
EP2568809A4 (de) 2010-05-12 2013-11-06 Univ Vanderbilt Heterozyklische allostere sulfon-mglur4-potentiatoren, zusammensetzungen und verfahren zur behandlung neurologischer dysfunktionen
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
WO2014070976A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
HUE035739T2 (en) 2013-01-14 2018-05-28 Molecular Insight Pharm Inc Triazine-based radiopharmaceuticals and radiological imaging agents
PH12018501979B1 (en) 2016-04-06 2023-05-05 Innovative Molecules Gmbh Aminothiazole derivatives useful as antiviral agents
PL3692039T3 (pl) 2017-10-05 2023-04-17 Innovative Molecules Gmbh Enancjomery podstawionych tiazoli jako związki przeciwwirusowe
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
CN114667285B (zh) 2019-09-26 2025-08-08 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
CN117695281B (zh) * 2023-12-26 2024-06-21 广州医科大学 四氢喹啉酮-酰胺-噻唑类化合物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8148047A0 (it) * 1981-03-18 1981-03-18 Manetti & Roberts Italo Brit Composti organici derivati da 2-ami no-5-(o-solfamidofenil)-1,3,4-tiadiazolo loro applicazione terapeutica e procedimento per la loro preparazione
ES2019294B3 (es) * 1985-12-16 1991-06-16 Lilly Co Eli Agentes antiviricos de tialiazol.
AU3886493A (en) * 1992-04-22 1993-11-18 Karin Elisabeth Peuschel Immuno-activating and hence anti-viral effect of 4-{3-(subst.-amino)-2-hydroxypropoxy}-1,2,5-thiadiazole compounds
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
JPH07188017A (ja) * 1993-09-30 1995-07-25 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体を含有する抗ウイルス剤
US5948916A (en) * 1994-09-22 1999-09-07 Rational Drug Design Laboratories Arylthiadiazole derivative and antiviral agent containing the same

Also Published As

Publication number Publication date
US6150385A (en) 2000-11-21
WO1999047507A2 (en) 1999-09-23
AU743489B2 (en) 2002-01-24
NZ507032A (en) 2003-06-30
DK1064273T3 (da) 2003-03-31
AU3063999A (en) 1999-10-11
DE69904576T2 (de) 2003-07-10
CA2320167A1 (en) 1999-09-23
ES2189404T3 (es) 2003-07-01
EP1064273B1 (de) 2002-12-18
WO1999047507A3 (en) 1999-12-09
EP1064273A2 (de) 2001-01-03
JP2002506858A (ja) 2002-03-05
DE69904576D1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
DE69904576D1 (de) Zur behandlung von cmv infektionen geeignete 1,3,4-thiadiazole
PL341364A1 (en) 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
ES2139195T3 (es) Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
EA200000840A1 (ru) Антивирусные производные пиримидина
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
BR9908332A (pt) Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
PT810209E (pt) Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
DK1200418T3 (da) Nematodicide trifluorbutener
NZ502988A (en) 5-Acetamido-4-amino-2-propionyloxy-6-isopropoxy-1-cyclohexene useful for treating influenza
AU667593B2 (en) Inhibitors of HIV protease useful for the treatment of AIDS
AU7713891A (en) Use of substituted 1,2,4-triazinediones
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
NZ308398A (en) 2-amino benzoxazin-4-one derivatives and medicaments
FI935779A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
EA200100711A1 (ru) Аналоги нуклеозида (варианты) и их применение, комбинация и способ лечения вирусных инфекций, фармацевтическая композиция
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
PY0101564A (es) Triazine containing anionic compounds useful as antiviral agents
GB2340490A (en) Diphenylacetic acid derivatives and their use as antiviral agents
PT1140932E (pt) Derivados de 1,8-benzonaftiridina
CY1112574T1 (el) Οκταπεπτιδιο το οποιο εχει αντιαγγειογενετικη δραστικοτητα
ECSP972314A (es) Derivados de aminoacidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064273

Country of ref document: EP

REN Ceased due to non-payment of the annual fee